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Abstract: Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of
death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains
a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant
(MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede
treatment success. An underexplored class of natural products—the capuramycin-type nucleoside
antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I,
a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review
discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin
and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB
therapeutic that warrants further development.
Keywords: natural product; nucleoside; antibiotic; MraY; bacterial translocase I; Mycobacterium tuberculosis

1. Introduction
Tuberculosis (TB), primarily caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb), is
one of the oldest and deadliest infectious diseases known to humans. The World Health Organization
(WHO) has recently reported that TB affected approximately 10 million people and killed roughly
1.3 million people in 2017 alone [1–4]. Although global TB-related mortality rates have steadily
declined since the turn of the millennium, multidrug-resistant (MDR), extensively drug-resistant
(XDR), and totally drug-resistant (TDR) strains pose significant threats to this progress [1,3,5–9].
Consequently, there is an urgent need for discovering new therapeutics to treat TB, which will in part
help to offset the diminishing utility of the antibiotics currently used to treat TB. Capuramycin-type
nucleoside antibiotics, which represent one such possible new class, are natural products that were
re-discovered in the early 2000s and have significant promise for drug development as anti-TB
therapeutics. This review summarizes the discovery of the capuramycin-type nucleoside antibiotics;
progress toward defining their biosynthetic pathway; and synthetic, semisynthetic, and biocatalytic
studies aimed at generating analogs with potentially improved therapeutic value. For an in depth
description of Mtb and tuberculosis, including the major challenges in drug discovery and development,
we refer the reader to several excellent reviews [10–14] and publications cited herein.
2. Discovery, Mechanism of Action, and Structure of Capuramycin-Type Nucleoside Antibiotics
Bacterial translocase I (annotated as MraY in Escherichia coli, MurX in Mtb, and herein simply
abbreviated as TL1) is an unusual transmembrane enzyme that catalyzes the first committed membrane
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Bacterial translocase I (annotated as MraY in Escherichia coli, MurX in Mtb, and herein simply
abbreviated as TL1) is an unusual transmembrane enzyme that catalyzes the first committed
step of peptidoglycan
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Bank ID: 4J72; [18]). aa L-Lys or L-diaminopimaleic acid (L-Dap) is found at this position depending on
Bank ID: 4J72; [18]). L-Lys or L-diaminopimaleic acid (L-Dap) is found at this position depending on
the genus of bacteria.
the genus of bacteria.

Three related groups of nucleoside-containing natural products were discovered by Sankyo
Three related groups of nucleoside-containing natural products were discovered by Sankyo Co.
Co. and named A-500359s (Figure 2A, 1 to 5, 8 to 10), produced by Streptomyces griseus SANK
and named A-500359s (Figure 2A, 1 to 5, 8 to 10), produced by Streptomyces griseus SANK 60196; A60196; A-503083s (6, 7, 11, and 12), produced by Streptomyces sp. SANK 62799; and A-102395 (13),
503083s (6, 7, 11, and 12), produced by Streptomyces sp. SANK 62799; and A-102395 (13), produced by
produced by Amycolatopsis sp. SANK 60206. Structural elucidation of A-500359s revealed three distinct
Amycolatopsis sp. SANK 60206. Structural
elucidation of A-500359s revealed three distinct chemical
chemical components: A uridine-50 -carboxamide (CarU), an unsaturated α-D-manno-pyranuronate,
components: A uridine-5'-carboxamide (CarU), an unsaturated α-D-manno-pyranuronate, and Land L-aminocaprolactam (L-ACL). A-500359 B (1) was shown to be identical to a known natural
aminocaprolactam (L-ACL). A-500359 B (1) was shown to be identical to a known natural product
product named capuramycin, which was discovered in 1986 from Streptomyces griseus 446-S3 as part of
named capuramycin, which was discovered in 1986 from Streptomyces griseus 446-S3 as part of a
a search for antibacterial agents [32,33]. Hence, we have termed the three groups as capuramycin-type
search for antibacterial agents [32,33]. Hence, we have termed the three groups0 as capuramycin-type
antibiotics. The A-503083s differ from the A-500359s by the presence of a 2 -O-carbamoyl group,
antibiotics. The A-503083s differ from the A-500359s by the presence of a 2’-O-carbamoyl group,
which has a minimal effect on TL1 inhibition and anti-TB activity. For both A-500359s and A503083s,
which has a minimal effect on TL1 inhibition and anti-TB activity. For both A-500359s and A503083s,
deaminocaprolactam derivatives 8 to 12 were isolated from the producing strains, and these analogs
deaminocaprolactam derivatives 8 to 12 were isolated from the producing strains, and these analogs
were shown to have significantly reduced inhibitory activity against TL1 as well as reduced antibiotic
were shown to have significantly reduced inhibitory activity against TL1 as well as reduced antibiotic
activity. Nucleoside 13 differs from the other two groups by containing an arylamine-linked polyamide
activity. Nucleoside 13 differs from the other two groups by containing an arylamine-linked
chain instead of the L-ACL. This substitution imparts 13 with the most potent TL1 inhibition
polyamide chain instead of the L-ACL. This substitution imparts 13 with the most potent TL1
(IC50 = 10 nM) of the three groups but effectively eliminates all antibiotic activity including against Mtb.
inhibition
(IC50 = 10 nM) of the three groups but effectively eliminates all antibiotic activity including
The shared CarU and 4,5-dehydro-D-manno-pyranuronate of the capuramycin-type nucleoside
against Mtb.
antibiotics are structural components not found in other natural products [34,35]. The former
is categorized as a high-carbon sugar nucleoside since the furanoside contains six contiguous
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and 4,5-dehydro-D-manno-pyranuronate of the capuramycin-type nucleoside
antibiotics are structural components not found in other natural products [34,35]. The former is
categorized as a high-carbon sugar nucleoside since the furanoside contains six contiguous carbons
carbons in place of the D-ribose of the canonical uridine nucleoside. Several other, structurally
in place of the D-ribose of the canonical uridine nucleoside. Several other, structurally distinct highdistinct high-carbon sugar nucleosides are known, including another category of TL1 inhibitors
carbon sugar nucleosides are known, including another category of TL1 inhibitors highlighted by a
highlighted by a high-carbon sugar nucleoside of seven contiguous carbons, 50 -C-glycyluridine (GlyU).
high-carbon sugar nucleoside of seven contiguous carbons, 5’-C-glycyluridine (GlyU). The GlyUThe GlyU-containing TL1 inhibitors, represented by the liposidomycin-type nucleoside antibiotics that
containing TL1 inhibitors, represented by the liposidomycin-type nucleoside antibiotics that includes
includes A-90289s and caprazamycins (Figure 2B), also have anti-TB activity in addition to efficacy
A-90289s and caprazamycins (Figure 2B), also have anti-TB activity in addition to efficacy against
against other bacteria [36,37]. Another example of a group of natural products containing a high-carbon
other bacteria [36,37]. Another example of a group of natural products containing a high-carbon sugar
sugar nucleoside is the polyoxins (Figure 2C), which contain six contiguous carbons in place of the
nucleoside is the polyoxins (Figure 2C), which contain six contiguous carbons in place of the D-ribose
D -ribose of the canonical uridine [38]. In contrast to CarU, however, C-6’ of the polyoxin nucleoside is
of the canonical uridine [38]. In contrast to CarU, however, C-6’ of the polyoxin nucleoside is a
a carboxylate that is part of a terminal α-amino acid. Unlike CarU- and GlyU-containing nucleoside
carboxylate that is part of a terminal α-amino acid. Unlike CarU- and GlyU-containing nucleoside
antibiotics, polyoxins do not inhibit TL1 but instead have antifungal activity due to selective inhibition
antibiotics, polyoxins do not inhibit TL1 but instead have antifungal activity due to selective
of chitin synthase [39].
inhibition of chitin synthase [39].
A)
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Figure 2. Structures of high-carbon sugar nucleosides. (A) Structure of the three major groups (AFigure 2. Structures of high-carbon sugar nucleosides. (A) Structure of the three major groups
500359s, A-503083s, and A-102395) of capuramycin-type nucleoside antibiotics isolated from different
(A-500359s, A-503083s, and A-102395) of capuramycin-type nucleoside antibiotics isolated from
bacterial strains. (B) Structure of representative 5’-C-glycyluridine (GlyU)-containing nucleoside
different bacterial strains. (B) Structure of representative 50 -C-glycyluridine (GlyU)-containing
antibiotics. (C) Structure of the antifungal compound polyoxin A.
nucleoside antibiotics. (C) Structure of the antifungal compound polyoxin A.
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3.2. Identification of the Gene Cluster
3.2. Identification of the Gene Cluster
The biosynthetic gene clusters for A-500359s and A-503083s were reported in 2009 and 2010,
The biosynthetic gene clusters for A-500359s and A-503083s were reported in 2009 and 2010,
respectively [41,42]. The gene cluster for the A-500359s was first identified using reverse transcription
respectively [41,42]. The gene cluster for the A-500359s was first identified using reverse transcription
polymerase chain reaction (RT-PCR) with degenerate primers designed to amplify DNA fragments
polymerase chain reaction (RT-PCR) with degenerate primers designed to amplify DNA fragments
encoding putative NDP-glucose-4,6-dehydratases (NGDH) [43], despite not having a clear role for
encoding putative NDP-glucose-4,6-dehydratases (NGDH) [43], despite not having a clear role for
such an enzyme activity in A-500359 biosynthesis. Several high, low, and non-producing strains were
such an enzyme activity in A-500359 biosynthesis. Several high, low, and non-producing strains were
initially generated by chemical mutagenesis, thus providing a correlation of the abundance of the PCR
initially generated by chemical mutagenesis, thus providing a correlation of the abundance of the
product versus production of A-500359s. A fragment of a putative NDGH that was over-expressed in
PCR product versus production of A-500359s. A fragment of a putative NDGH that was overthe high-producing strains and absent in non-producing strains was subsequently cloned to create a
expressed in the high-producing strains and absent in non-producing strains was subsequently
digoxigenin (DIG)-labeled fragment, which was then used to probe a genomic library. Two contiguous
cloned to create a digoxigenin (DIG)-labeled fragment, which was then used to probe a genomic
cosmids were identified and sequenced to reveal a 65-kb DNA region encoding 38 putative open
library. Two contiguous cosmids were identified and sequenced to reveal a 65-kb DNA region
reading frames (orfs) (NCBI Accession No. AB476988). RT-PCR analysis was again utilized to analyze
encoding 38 putative open reading frames (orfs) (NCBI Accession No. AB476988). RT-PCR analysis
the expression of these 38 orfs within the different producing and non-producing strains, revealing that
was again utilized to analyze the expression of these 38 orfs within the different producing and non26 orfs were likely involved in A-500359 biosynthesis, regulation, and resistance. The development
producing strains, revealing that 26 orfs were likely involved in A-500359 biosynthesis, regulation,
of a genetic system within the 1 producing strain was unsuccessful. Therefore, to provide additional
and resistance. The development of a genetic system within the 1 producing strain was unsuccessful.
evidence that the correct genomic locus was identified, one of these orfs—orf21 encoding a putative
Therefore, to provide additional evidence that the correct genomic locus was identified, one of these
aminoglycoside phosphotransferase—was heterologously expressed in 1-sensitive strains to reveal the
orfs—orf21 encoding a putative aminoglycoside phosphotransferase—was heterologously expressed
gene product confers selective resistance to 1.
in 1-sensitive strains to reveal the gene product confers selective resistance to 1.
To provide convincing evidence that the gene cluster for the capuramycin-type nucleoside
To provide convincing evidence that the gene cluster for the capuramycin-type nucleoside
antibiotics was identified, the gene cluster for the A-503083s was targeted for cloning and
antibiotics was identified, the gene cluster for the A-503083s was targeted for0 cloning and
characterization [42]. As previously noted, A-503083s—unlike A-500359s—contain a 2 -O-carbamoyl
characterization [42]. As previously noted, A-503083s—unlike A-500359s—contain a 2’-O-carbamoyl
group, and it was therefore expected that a functional carbamoyltransferase was encoded within
group, and it was therefore expected that a functional carbamoyltransferase was encoded within the
the gene cluster. Interestingly, the gene cluster for A-500359s encodes an orf (orf8) with sequence
gene cluster. Interestingly, the gene cluster for A-500359s encodes an orf (orf8) with sequence
similarity to known carbamoyltransferases, but the orf8 gene product appears to be missing ~50% of
similarity to known carbamoyltransferases, but the orf8 gene product appears to be missing ~50% of
the internal sequence when compared to typical carbamoyltransferases. The orf8 gene remnant—along
the internal sequence when compared to typical carbamoyltransferases. The orf8 gene remnant—
with another expression-correlated orf encoding a putative nonribosomal peptide synthetase—were
along with another expression-correlated orf encoding a putative nonribosomal peptide synthetase—
utilized as probes to isolate four contiguous cosmids from the genomic DNA of the producing strain
were utilized as probes to isolate four contiguous cosmids from the genomic DNA of the producing
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Table 1. Shared orfs within the cloned biosynthetic gene clusters.
Table 1. Shared orfs within the cloned biosynthetic gene clusters.
Proposed Function
A-500359
A-503083
Proposed Function
A-500359
A-503083
Fe(II)- and αKG-dependent dioxygenase
orf7
capD
0 -O-carbamoyltransferase
Fe(II)-Capuramycin-2
and αKG-dependent
dioxygenase
orf8orf7
capBcapD
Putative
3-ketoreductase
orf9
capC
Capuramycin-2‘-O-carbamoyltransferase
orf8
capB
Fe(II)-dependent,
αKG:UMP dioxygenase
orf10
capAcapC
Putative
3-ketoreductase
orf9
Putative 2,3-dehydratase
orf11
capE
Fe(II)-dependent,
αKG:UMP dioxygenase
orf10
Putative 4-epimerase
orf12
capFcapA
Putative
2,3-dehydratase
orf11
capE
PLP-dependent
monooxygenase-decarboxylase
orf12’
cap15
Putative
glycosyl
transferase
orf13
capG
Putative 4-epimerase
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F (11). Feeding the mutant strain with L-ACL restored the production of 6 and 7, revealing that
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the results
provided
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producing
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system
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that successful.
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of
producer
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was initially
The
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gene,
encoding
a tridomain
nonribosomal
peptide synthetase that was predicted to be involved in L-ACL formation, was inactivated [44]. The
corresponding capU strain was unable to produce the L-ACL-containing A-503083 A (6) and A503083 B (7) but instead produced relatively high levels of the deaminocaprolactam analog A-503083
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A-503083s. Unfortunately, additional attempts to make other mutations within the producing strain of
the A-503083s have failed for unknown reasons.
The 13 gene cluster was identified in 2015 from a cosmid DNA library using a DIG-labeled
fragment of the L-Thr:uridine-50 -aldehyde transaldolase gene, which had already been characterized
from the gene cluster of the A-500359s and A-503083s and shown to be necessary for the biosynthesis
of the CarU moiety [45,46]. Four cosmids were sequenced, revealing 76 orfs within ~85-kb genomic
DNA (NCBI Accession No. KP995196). Of the identified orfs, 40 were proposed to be likely responsible
for the biosynthesis of 13; however, only 16 orfs were found to be shared among all three groups
of capuramycin-type antibiotics (Table 1). Therefore, it is proposed that 15 orfs are involved in the
biosynthesis of A-500359E (8), the likely last shared intermediate of all three biosynthetic pathways,
and one orf (cpr51) was responsible for the attachment of the polyamide via aminolysis. Similar to
the producing strain for A-503083s, a genetic system has been developed within the 13 producing
strain. Both ∆cpr25 and ∆cpr51 mutant strains have been independently prepared, and both mutations
abolished the production of 13. However, attempts to isolate biosynthetic intermediates or genetically
complement these mutations have so far been unsuccessful.
3.3. Functional Assignment of Gene Products
Insight into the biosynthesis of CarU was obtained from the independent efforts to characterize
the biosynthetic mechanism of the GlyU component of the liposidomycin-type nucleoside antibiotics.
Utilizing recombinant enzymes from the biosynthetic pathway for A-90289s, GlyU was shown to
be derived from UMP via two sequential enzyme-catalyzed reactions (Figure 5A). The first reaction
is catalyzed by LipL, a non-heme Fe(II)- and α-ketoglutarate (αKG)-dependent dioxygenase [47].
LipL stereoselectively hydroxylates C-50 of UMP, resulting in the elimination of phosphate with
concomitant formation of the first pathway intermediate, uridine-50 -aldehyde (UA) [48]. Subsequently,
LipK, predicted to be a pyridoxal-50 -phosphate (PLP)-dependent serine hydroxymethyltransferase,
functions as a transaldolase by catalyzing the conversion of L-Thr and UA to GlyU and
acetaldehyde [45]. The LipK-catalyzed reaction was shown to be stereoselective both in the selection
of the L-Thr substrate and the formation of (50 S,60 S)-GlyU. Comparative bioinformatic analysis
revealed homologs to both LipL and LipK are encoded within the gene cluster for each group of
capuramycin-type antibiotics, suggesting that CarU is derived from UMP by way of (50 S,60 S)-GlyU.
If this is indeed the case, the direct precursor of the carboxamide of CarU would be expected to be
L -Thr instead of phosphoenolpyruvate as previously proposed. Consequently, feeding experiments
to probe the origin of C-6’ were revisited. As predicted from bioinformatics, L-[13 C4 ,15 N]Thr, when
fed to the producing strain of the A-503083s, resulted in a 15% enrichment at C-60 of 7 (Figure 2) [46].
This level of enrichment is comparable to the levels for the enrichment of L-ACL with L-Lys, suggesting
that L-Thr is a direct precursor. Furthermore C-N J coupling suggested that the Cα -N bond of L-Thr
remained intact during CarU biosynthesis.
With this information in hand, the biosynthesis of CarU was examined using recombinant
enzymes. Cpr19, the LipK homolog encoded within the 13 gene cluster, was demonstrated to use
Fe(II), O2 , and αKG to convert UMP to UA (Figure 5A) [46]. CapH and Cpr25, the LipK homologs
encoded within the A-503083s and 13 gene clusters, respectively, catalyzed the identical (and expected)
chemistry: the conversion of UA to (50 S,60 S)-GlyU, thus supporting the results from the feeding
experiments. The formation of (50 S,60 S)-GlyU as a pathway intermediate suggested downstream
chemistry involving C-60 -decarboxylation—shortening the heptose to a hexose, the introduction of
an O atom at C-60 , and oxidation. Given the precedence for PLP-dependent enzymes in catalyzing
decarboxylation of α-amino acids, the three gene clusters were analyzed for potential shared candidates
with a predicted PLP dependency. This search revealed one unassigned gene product (Cap15
for the biosynthesis of A-503083s) with similarity to bacterial PLP-dependent L-seryl-tRNA (Sec)
selemium transferase, which catalyzes the β-replacement of the hydroxyl group of tRNA-loaded L-Ser
with Se using selenophosphate as the Se source. However, no reaction was observed when Cap15
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was incubated with (50 S,60 S)-GlyU. Rather, serendipitously, Cap15 was discovered to function as a
PLP-dependent monooxygenase-decarboxylase that directly converts (50 S,60 R)-GlyU directly to CarU
in a single reaction (Figure 5A) [49]. The finding that Cap15 is stereoselective for the 60 R-isomer
of GlyU suggests an epimerase is needed to convert the CapH product to the Cap15 substrate.
One potential candidate for this reaction is CapD, an unassigned Fe(II) and αKG-dioxgenase with low
sequence similarity to Cpr19. Other members of this large dioxygenase superfamily—for example,
CarC—are known to catalyze epimerization at carbon centers bonded to an amine, thereby providing
precedence for this putative functional assignment [50–52]. Further biochemical characterization of
Cap15 revealed other intriguing properties including that (i) the enzyme activates molecular oxygen
using a substrate-PLP aldimine as the initial reducing agent, an unusual example of the use of the PLP
cofactor as a redox cofactor and (ii) the activity was dependent upon phosphate despite no obvious
role
in the
chemistry
[49].
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The enzymes required for the biosynthesis of the α-D-manno-pyranuronate component of the
With this information in hand, the biosynthesis of CarU was examined using recombinant
capuramycin-type nucleoside antibiotics remain to be functionally assigned. If the moiety is derived
enzymes. Cpr19, the LipK homolog encoded within the 13 gene cluster, was demonstrated to use
from D-mannose as the feeding experiments would suggest, the most direct path would involve
Fe(II), O2, and αKG to convert UMP to UA (Figure 5A) [46]. CapH and Cpr25, the LipK homologs
a four-electron oxidation of C-6, a 4,5-dehydration, and glycosyltransfer to CarU. Analysis of the
encoded within the A-503083s and 13 gene clusters, respectively, catalyzed the identical (and
expected) chemistry: the conversion of UA to (5′S,6′S)-GlyU, thus supporting the results from the
feeding experiments. The formation of (5′S,6′S)-GlyU as a pathway intermediate suggested
downstream chemistry involving C-6′-decarboxylation—shortening the heptose to a hexose, the
introduction of an O atom at C-6′, and oxidation. Given the precedence for PLP-dependent enzymes
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biosynthetic gene clusters revealed several gene products with similarity to enzymes involved bacterial
sugar biosynthetic pathways, including a putative glycosyltransferase (CapG for A-503083) that could
catalyze the last step. However, it is not obvious how the other gene products, namely CapC, CapE, and
CapF for A-503083s, would contribute to the expected chemistry, which we propose begins from the
precursor GDP-mannose (Figure 5B). Nonetheless, the isolation of a taluronic acid-containing congener
of A-500359 H (10) called A-500359 J (14) suggests 4,5-dehydration occurs after CapG-catalyzed
transfer to the acceptor, CarU [20]. Additionally, this pathway would necessitate C-40 epimerization to
generate GDP-taluronic acid, although it is not clear whether this occurs before or after glycosyltransfer.
As previously noted, the NDGH-like protein is not expected to play a role in α-D-manno-pyranuronate
biosynthesis since (i) a 4,6-dehydration catalyzed by the canonical NDGH is apparently not needed
and (ii) an NDGH homolog is not encoded within the 13 gene cluster.
The formation and attachment of the L-ACL moiety of the A-500359s and A-503083s has
been defined using enzymes from the biosynthetic pathway for A503083s, revealing two different
mechanisms for amide bond formation. The initial step in the biosynthesis involves a traditional
ATP-dependent reaction catalyzed by CapU: adenylation and transfer of L-Lys to the sulfhydryl
group of the carrier protein domain located at the C-terminus of CapU followed by intramolecular
aminolysis to release the lactam, the latter step of which appears to be nonenzymatic (Figure 5C) [44].
The subsequent step, the attachment of the L-ACL, involves an unusual ATP-independent
transacylation mechanism [42]. CapS first catalyzes an AdoMet-dependent carboxyl methylation
of 9 to generate the methyl ester A-500359 E (8). This reaction effectively “activates” the carboxylate
such that CapW—a protein with sequence similarity to AmpC β-lactamases that employ an active
site Ser residue to generate an acyl enzyme intermediate during the reaction coordinate—catalyzes
transacylation to produce methanol and the L-ACL-containing 1. Despite a dramatic difference in the
structure, the aryl-containing polyamide of 13 is expected to be attached in a similar manner due to
the uncovering of homologs of the carboxylmethyltransferase (Cpr27) and transacylase (Cpr51) [46].
However, enzymes catalyzing these putative reactions or any reactions involved in the biosynthesis of
the polyamide of 13 have been characterized to date. Finally, we propose that O-methylation of the
C-30 -hydroxyl is catalyzed by CapK and occurs prior to the attachment of the L-ACL since compounds
8 and 9 are isolated as the major congeners. However, the L-ACL-containing congener A-500359 G
(5) is produced in small amounts [24], suggesting either the amide coupling enzymes have relaxed
specificity toward this modification or the methylation can occur post L-ACL attachment.
Three enzyme-catalyzed group transfer reactions occur following the synthesis of 1, two of which
have been characterized in vitro (Figure 5D). CapB, the predicted full-length carbamoyltransferase
that was used in part to identify the biosynthetic gene cluster for the A-503083s, catalyzes the
carbamoyl phosphate-dependent addition of a carbamoyl group to the C-20 hydroxyl to convert 1 to 7
(assuming this “tailoring” step occurs first) [42]. CapT, a putative radical SAM C-methyltransferase,
likely catalyzes the stereoselective methylation of the L-ACL, thereby converting 7 to 6 (assuming
this reaction follows CapB). Finally, CapP was functionally assigned as an ATP-dependent 7
300 -O-phosphotransferase that was shown to likely confer self-resistance to the producing strain [53].
Cpr17, the CapP homolog in the 13 biosynthetic pathway, was similarly demonstrated to have an
identical phosphotransferase function [54]. Nonetheless, phosphorylated capuramycin analogs have
not been isolated from the producing strains.
4. Chemical and Enzymatic Synthesis of Capuramycin and Analogs
Since the structural elucidation of capuramycin in 1988 [33], a few total syntheses have been
independently reported. Moreover, a large library of analogs prepared via semisynthesis, total
synthesis, and biocatalysis have been screened for antibacterial activity. These efforts, which have
resulted in the advancement of a few lead compounds for further development, are described below.
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4.2. Preparation of 1 Analogs
4.2. Preparation of 1 Analogs.
The synthesis of analogs of 1 (Table 2) was initially pursued shortly after the discovery of 1 to 12
The synthesis of analogs of 1 (Table 2) was initially pursued shortly after the discovery of 1 to 12
using a semisynthetic strategy to substitute the L-ACL component by starting with congener 8 [59].
using a semisynthetic strategy to substitute the L-ACL component by starting with congener 8 [59].
With strong nucleophilic amines, a single-step aminolysis reaction afforded the products in decent
With strong nucleophilic amines, a single-step aminolysis reaction afforded the products in decent
yields. Alternatively, a multistep protection-deprotection sequence that included saponification and
yields. Alternatively, a multistep protection-deprotection sequence that included saponification and
condensation was utilized. Sixty-eight capuramycin analogs, represented by 19 to 26, were prepared.
condensation was utilized. Sixty-eight capuramycin analogs, represented by 19 to 26, were prepared.
A few of these analogs displayed improved TL1 inhibition and antibacterial activity against various
A few of these analogs displayed improved TL1 inhibition and antibacterial activity against various
Mycobacterium species including M. smegmatis, M. avium, M. intracellulare, and M. kansasii [31]. Of the
analogs tested, 24 (compound 65 in the original paper), which has a 3,4-difluoroaniline in place of the
L -ACL, showed improved MIC values (0.5 to 2 µg/mL compared to 8 to 12.5 µg/mL for 1).
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Table 2. Antimycobacterial activities of several capuramycin analogs prepared through semisynthesis.

Compound

R1

R2

R3

20
21
22
23
24
25
26
27
28
1
2
RIF 2
IZD 3

PhNHPhN(Me)3-F-PhNH4-F-PhNH3,4-F2 -PhNH4-Cl-PhNH4-Br-PhNH-

H
Me

H(CH2 )11 COH(CH2 )9 CO-

TL1 IC50
(ng/mL)
6.5
7.6
10
37
9
18
20
n.d.
550
10
10

MIC (µg/mL) 1
Strain A

Strain B

Strain C

Strain D

6.25
12.5
6.25
6.25
6.25
6.25
6.25
3.13
6.25
12.5
6.25
n.d.
n.d.

16
4
2
4
2
4
8
<0.063
<0.063
8
8
0.125
1

4
1
2
2
0.5
2
0.5
0.125
<0.063
8
4
0.125
8

8
8
8
2
1
16
8
0.125
<0.063
8
16
0.25
2

1

Strain A: M. smegmatis SANK75075; strain B: M. avium NIHJ1605; strain C: M. intracellulare ATCC19543; strain D:
M. kansasii ATCC12478; 2 Rifampicin; 3 Isoniazid

Additional studies focused on the modification of the 20 -hydroxyl of 1 and 2 by introducing
different acyl, alkoxycarbonyl, or alkylether groups in three to five steps (Table 2) [60]. Fifty-one
analogs were synthesized and tested for antimycobacterial activity with a few showing improved
activity compared to the parent compounds (Table 2). Among them, 28 (compound 20 in the original
paper), which has a decanoyl chain, showed improved MIC against the four species of Mycobacterium.
Interestingly, 28 was 55-fold less potency against TL1 when compared to the parent compound, 2.
The improved MIC of 28 was hypothesized to be due to the increased lipophilicity that results in the
effective penetration of the Mtb cell wall, thus compensating for the decrease in IC50 (assuming the
acyl group remains intact, which remains to be determined). Indeed, the penetration of Mtb cell walls
has been a major challenge in the field of anti-TB drug discovery, and comparable acylation strategies
for other drug classes of potential anti-TB drugs have been shown to have a similar effect [61,62].
In total, over 7000 capuramycin analogs were synthesized using different combinations of
the aforementioned semisynthetic approaches and screened for antimycobacterial activity [63,64],
ultimately yielding 24 (named RS-124922 by Sankyo Co.; renamed to SQ922 by Sequella Inc. after
licensing the library), and 28 (RS-118641; SQ641) as leads [65,66]. In comparison to parent 2 (RS-112997;
SQ997), compound 28 displayed a significantly improved antimycobacterial activity with MICs as
follows: 1 µg/mL against non-MDR Mtb (n = 22 clinical isolates; 16 µg/mL for 2), 0.5 µg/mL against
MDR-Mtb (n = 11; 16 µg/mL for 2), 4 µg/mL against M. avium (n = 33; 8 µg/mL for 2), and 0.06 µg/mL
against M. intracellulare (n = 17; 2 µg/mL for 2) [65]. By further examining the activity against Mtb
H37Rv, compounds 24 and 28 were shown to kill faster than other clinically used anti-TB drugs
including isoniazid and rifampicin [65]. Both analogs appear to induce bacteriolysis of Mtb, and 28 had
a clear post-antibiotic effect that lasted as long as 55 h. Compound 28 also showed synergistic activity
with other anti-TB drugs, including streptomycin and ethambutol [65]. Finally, when formulated with
a vitamin E derivative or as micelles and tested in vivo, 28 displayed ~2 log reduction in burden using
a murine lung model of Mtb H37Rv infection [66]. No noticeable toxicity was observed.
The impact of different long chain ester modifications at the 20 , 200 , and/or 300 positions of 2,
24, and 28 has been explored as a strategy to improve activity against mycobacteria and extend
the antibiotic spectrum (Figure 7) [67,68]. Promising results were obtained when conjugated
with decanoic acid (DEC) or amino undecanoic acid (AUA) exemplified by compounds 29 to
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acylation of the reactive hydroxyl groups of 2. The semisynthetic strategy has led to the discovery of
a few analogs such as 24 and 28 that have superior activity against Mtb in comparison to the parent.
Furthermore, some of the analogs have an extended spectrum of activity, suggesting the development
of capuramycin-type nucleoside antibiotics is not limited to mycobacteria. Formulation and delivery
studies [73–76] have further improved the solubility and pharmacodynamics of some of these lead
compounds, thereby pushing this family further down the translational pipeline.
Total synthesis and enzymatic synthesis have more recently emerged as two alternative strategies
to generate capuramycin analogs. Importantly, both strategies afford an opportunity to probe the
structure–activity relationship of core components of the capurmaycin scaffold in greater detail.
The former approach has enabled the synthesis of new L-ACL-substituted analogs and the dimethylated
analog 38. The latter approach has enabled a chemoenzymatic strategy to likewise synthesize
new L-ACL-substituted analogs. Unfortunately, most of the enzyme-catalyzed steps involved in
capuramycin biosynthesis remain undefined, particularly with respect to the formation and attachment
of the α-D-manno-pyranuronate. As our understanding of the biosynthetic pathway improves, it is
expected that capuramycin scaffolds altered within the α-D-manno-pyranuronate or elsewhere can be
readily prepared through enzymatic synthesis, thereby generating a new array of analogs that will be
valuable for continued anti-TB drug discovery efforts.
Funding: This research was funded by National Institutes of Health, grant number AI128862 and AI087849 and
National Natural Science Foundation of China, grant numbers 81321004 and 81761128016.
Conflicts of Interest: The authors declare no conflict of interest.
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